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High numbers of mobilized CD34+ cells collected in AML in
ﬁrst remission are associated with high relapse risk irrespective
of treatment with autologous peripheral blood SCT or
autologous BMT
M Hengeveld1, S Suciu2, Y Chelgoum3, J-P Marie4, P Muus1, F Lefrère5, F Mandelli6, F Pane7, S Amadori8, G Fioritoni9, B Labar10,
F Baron11, J Cermak12, J-H Bourhis13, G Storti14, P Fazi15, A Hagemeijer16, M Vignetti15, R Willemze17 and T de Witte1
The faster hematopoietic recovery after autologous peripheral blood SCT (APBSCT) in patients with AML may be offset by an
increased relapse risk as compared with autologous BMT (ABMT). The EORTC and GIMEMA Leukemia Groups conducted a trial
(AML-10) in which they compared, as second randomization, APBSCT and ABMT in ﬁrst CR patients without an HLA compatible
donor. A total of 292 patients were randomized. The 5-year DFS rate was 41% in the APBSCT arm and 46% in the ABMT arm with a
hazard ratio (HR) of 1.17; 95% conﬁdence interval = 0.85–1.59; P= 0.34. The 5-year cumulative relapse incidence was 56% vs 49%
(P= 0.26), and the 5-year OS 50% and 55% (P= 0.6) in the APBSCT and ABMT groups, respectively. APBSCT was associated with
signiﬁcantly faster recovery of neutrophils and platelets, shorter duration of hospitalization, reduced need of transfusion packed
RBC and less days of intravenous antibiotics. In both treatment groups, higher numbers of mobilized CD34+ cells were associated
with a signiﬁcantly higher relapse risk irrespective of the treatment given after the mobilization. Randomization between APBSCT
and ABMT did not result in signiﬁcantly different outcomes in terms of DFS, OS and relapse incidence.
Bone Marrow Transplantation (2015) 50, 341–347; doi:10.1038/bmt.2014.262; published online 17 November 2014
INTRODUCTION
Patients with AML in ﬁrst CR (CR-1) usually receive post-remission
therapy to prevent relapse. Three treatment modalities are
generally applied: intensive consolidation chemotherapy, hema-
topoietic SCT or maintenance chemotherapy.1,2 Auto-SCT (ASCT)
resulted in a better outcome in terms of disease-free survival (DFS)
and relapse rate when compared with intensive consolidation
chemotherapy, but usually OS was not signiﬁcantly different,
partly due to a better response to second line therapy after
relapse.1–3 Nevertheless, several study groups consider ASCT as
the treatment of choice for intermediate and high-risk AML
patients if allo-SCT is not applicable.1,4–9 BM is the traditional stem
cell source for ASCT, but BM stem cells have been associated with
insufﬁcient harvests and prolonged hematopoietic hypoplasias in
a substantial number of patients with AML leading to low
compliance with this treatment modality.1,2 In most studies
comparing ASCT with chemotherapy autologous BM has been
used as the source of stem cells.10 Twenty-ﬁve years ago,11 G-CSF-
mobilized blood stem cells were introduced for autologous
peripheral blood SCT (APBSCT) leading to faster hematopoietic
recovery presumably due to higher numbers of infused CD34+
cells. A high relapse rate after ASCT using high numbers of PBSC
has been reported in single arm studies.12,13 A retrospective study
by the European Group for Blood and Marrow Transplantation
(EBMT) showed a higher relapse rate after using mobilized blood
stem cells compared with BM stem cells.14 A subsequent
retrospective registry study by the EBMT showed an association
between a high number of infused peripheral blood CD34+ cells
and an increased relapse rate and lower leukemia-free survival.15
The question is whether the increased relapse risk was because of
higher numbers of infused leukemic stem cells in these patients or
whether the number of collected stem cells just reﬂected the
sensitivity of the patient to chemotherapy resulting from genetic
polymorphisms to metabolize the administered cytotoxic drugs.16
The outcome after ASCT using peripheral blood rather than BM
stem cells has not been compared prospectively before. To
address the issue of a potentially increased relapse rate risk after
APBSCT, we amended the AML-10 trial4 for patients who were
candidates for ASCT in 1994. Patients in CR after remission-
induction chemotherapy were randomized between APBSCT and
autologous BMT (ABMT).
SUBJECTS AND METHODS
In the randomized phase III AML-10 trial of the EORTC and GIMEMA
Leukemia Groups,4 patients achieving CR after one or two induction
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courses with either DNR, mitoxantrone or idarubicin in combination with
cytarabine and etoposide in a 3+10+5 regimen, were treated subsequently
by one consolidation course. The consolidation course consisted of
intermediate dose cytarabine (500mg/m2, twice daily for 6 days) and
3 days of the randomized intercalating agent. Mobilization and collection
of autologous PBSC was scheduled during the recovery phase of the
consolidation course. Lenograstim (150 μg/m2) was given by daily s.c.
injections from day 20 of the consolidation course until completion of the
blood stem cell collections. Collections took place on 1 to 5 consecutive
days as soon as the leukocyte counts exceeded 2× 109/L or the CD34+
cells in the blood exceeded 2× 107/L. The total blood stem cell harvest
should contain at least 2 × 106/kg body weight CD34+ cells. Patients who
were randomized for ABMT underwent subsequently a BM harvesting
procedure. The randomization between APBSCT and ABMT took place
28 days after the start of the consolidation course irrespective of the
outcome of the mobilization. The study was approved by the ethics
committees of the participating institutions and was conducted in
accordance with the Declaration of Helsinki.
Randomization was performed centrally (EORTC Data Center, Brussels,
Belgium) using the minimization technique. Stratiﬁcation factors were:
institution, age (15–45 vs 46–60 years), treatment arm of ﬁrst randomiza-
tion, number of induction courses to reach a CR, cytogenetic groups at
diagnosis (Table 1).
All the patients were transplanted with unpurged stem cells after BM
ablative conditioning consisting of CY/TBI or CY/BU (Table 1). No
prophylactic hematopoietic growth factors were allowed after stem cell
infusion.
Primary endpoint was DFS. Secondary endpoints were time to relapse,
death without relapse, OS and hematologic recovery in terms of recovery
of neutrophils and platelets, duration of hospitalization, the need of i.v.
antibiotics or packed RBC.
Criteria for evaluation
CALGB criteria of response and of relapse were used.
RESULTS
A total of 292 patients, registered by 43 institutions,
were included in this study: 146 in each arm. The two treatment
groups were well balanced regarding all characteristics, as
indicated in Table 1. The median age was 44 years, ranging from
15–60 years.
Stem cell harvest of the randomized stem cell source was
successful in 105 patients (72%) of the APBSCT arm and in 86
patients (59%) of the ABMT arm. In the APBSCT arm, 103 patients
received APBSCT (72%), six patients received ABMT (4%), one
patient received APBSCT combined with matched unrelated donor
allograft rescue (1%) and 29 patients (20%) received no further
treatment, including 23 patients with no stem cell harvest. In the
ABMT arm, 71 patients received ABMT only (49%), 22 patients
received ABMT followed by APBSCT rescue (15%) according to
protocol, 17 patients received APBSCT (12%) and 28 patients
(19%) received no further treatment, including 12 patients with no
stem cell harvest (Figure 1). The mean (± s.d.) interval between
start of the consolidation course and the date of ASCT was longer
in the ABMT arm (103±50 days) than in the APBSCT arm
(89 ± 43 days). This may explain why only two patients relapsed
before the planned APBSCT and 12 patients before the planned
ABMT (Figure 1).
At the time of evaluation, 130 patients were still alive and in
CR-1, 150 patients have relapsed (79 in the APBSCT arm vs 71 in
the ABMT arm) and 12 patients have died in CR-1 (5 in the APBSCT
arm vs 7 in the ABMT arm). The DFS showed no signiﬁcant
difference between the two treatment arms (Figure 2); hazard
ratio (HR) of APBSCT vs ABMT was 1.16, 95% conﬁdence interval
(CI) = 0.85–1.58 (Table 2). Results remained unchanged by adjust-
ing the treatment comparison by factors, which appeared to be of
independent prognostic importance (cytogenetic features, perfor-
mance status at ﬁrst randomization, number of cycles to reach CR)
and other factors, used as stratiﬁcation of randomization (WBC
and initial randomized treatment). Model 3 (see Supplementary
Table 1) which took into consideration all the independent factors,
except the number of mobilized CD34+ cells, showed for DFS HR
of 1.17; 95% CI = 0.85–1.59 (P= 0.34) and for OS a HR of 1.11; 95%
CI = 0.79–1.56 (P= 0.55). The 5-year cumulative relapse incidence
was 56% in the APBSCT arm vs 49% in the ABMT arm, and the
relapse risk HR of APBSCT vs ABMT was 1.20 (log-rank P= 0.26).
The 5-year cumulative death in CR incidence was 4% (APBSCT
arm) vs 5% (ABMT arm) and the death in CR rate HR was 0.72.
A total of 135 patients died: 69 in the APBSCT arm and 66 in the
ABMT arm. The OS was similar between the two arms (Figure 2);
HR 1.09, 95% CI = 0.78–1.53 (Table 2). Results remained unchanged
by adjusting the analysis by cytogenetic features and number of
cycles to reach CR, which were of prognostic importance, and also
by performance status, WBC and initial randomized treatment (see
Supplementary Table 1).




No. (%) No. (%)
Total 146 (100) N= 146 (100)
Age at diagnosis, years
15–25 20 (13.7) 16 (11.0)
26–45 59 (40.4) 60 (41.4)
46–60 67 (45.9) 70 (47.9)
Sex
Male 69 (47.3) 76 (52.1)
Female 76 (52.0) 70 (47.9)
Missing 1 (0.7) —
Performance status at 1st randomization
0 61 (41.8) 54 (37.0)
1 68 (46.6) 74 (50.7)
2 15 (10.3) 16 (11.0)
3–4 1 (0.7) 1 (0.7)
Missing 1 (0.7) 1 (0.7)
White cell count × 109/L at diagnosis
o25 91 (62.3) 86 (58.9)
25 to o100 46 (31.5) 49 (33.6)
⩾ 100 9 (6.2) 11 (7.5)
Cytogenetic groupa
Good 26 (17.8) 32 (21.9)
Intermediate 44 (30.1) 42 (28.8)
Poor 11 (7.5) 15 (10.3)
Other 18 (12.3) 16 (10.6)
Inconclusive 47 (32.2) 41 (28.1)
Numbers of cycles to reach CR
1 135 (92.5) 132 (90.4)
41 7 (4.8) 9 (6.1)
Successful stem cell harvestb 105 (71.9) 86 (58.9)
Type of conditioningc 103 93
TBI based 65 55
Chemotherapy only 38 36
Abbreviations: ABMT= autologous BMT; APBSCT= autologous peripheral
blood SCT. aGood prognosis: t(8;21), inv(16), del(16), t(16;16); intermediate
prognosis: NN, -Y or -X only; poor prognosis:-7/7q-, − 5/5q-, complex, +8, Ph
+; others: other cytogenetic characteristics; inconclusive: technical failure
or not performed bSuccessful harvest of stem cell source in the
randomized arm. cOnly autografted patients with sufﬁcient data.
Auto-SCT for AML in ﬁrst CR
M Hengeveld et al
342
Bone Marrow Transplantation (2015) 341 – 347 © 2015 Macmillan Publishers Limited
Hematopoietic recovery and associated variables
The hematopoietic recovery was faster in the APBSCT arm: the
median number of days to reach ⩾ 20 × 109/L platelets was
23 days in the APBSCT arm vs 77 days in the ABMT arm
(Po0.0001; see also Supplementary Table 2). The median number
of days to reach ⩾ 0.5 × 109/L neutrophils was 22 days vs 42 days,
respectively (Po0.0001). The short hypoplasia after PB CD34+ cell
reinfusion resulted in a signiﬁcantly lower median number of
transfusions: three vs eight packs of RBC and 5 vs 34 packs of
platelets, and shorter median number of 11 days on intravenous
antibiotics in the APBSCT arm vs 19 days in the ABMT arm
(Po0.0001). The median duration of hospitalization was 24 days
vs 41 days, respectively (Po0.0001).
Impact of numbers of mobilized CD34+ cells on outcome
As a surrogate marker for the mobilizing capacity after consolida-
tion treatment, we used the highest CD34+ cell yield of a single
apheresis procedure during the ﬁrst mobilization round, which may
consist of several apheresis procedures (Table 2). The total number
of CD34+ cells collected during all subsequent mobilization rounds
could not be used for this purpose as this was inﬂuenced by the
predetermined target of 2 × 106 CD34+ cells/kg (Table 3).
Previously,17 we analyzed the DFS according to the number of
collected CD34+ cells, irrespective of the treatment administered
to the patient. In the present study, we compared the outcome
(DFS and DFI) in both treatment arms: APBSCT vs ABMT on an
intention-to-treat basis after adjustment for the number of CD34+
Randomised (n=292)
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Figure 1. Flow diagram of actual treatment given. Details of the treatment are given in the Subjects and Methods section.
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Figure 2. Duration of disease-free survival (a) and survival (b) from randomization in patients randomized to receiving mobilized autologous
PBSC (red curve) or autologous BM stem cells (blue curve). N=number of patients; O=observed number of events (relapse or death in CR-1);
P-value given by the log-rank test.
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cells, cytogenetics and number of courses to reach CR, age and
treatment to remission-induction treatment (Table 4; for more
details, see Supplementary Table 1). The number of CD34+ cells,
cytogenetic risk group and number of courses to reach CR were
independent prognostic factors. For exploratory purposes, we
performed subgroup analyses regarding DFS according to the two
ﬁrst factors using forest plot technique. This subgroup analysis
showed a consistent lack of treatment difference between APBSCT
and ABMT (Figure 3). On the other hand, the magnitude of the
CD34+ cell yield during the ﬁrst apheresis was of prognostic
importance in each randomized arm, and in each transplanted
group (ABMT only, APBSCT only, ABMT±APBSCT, APBSCT ± BMT),
as those with a highest yield (47 × 106/kg) appeared to have the
worst outcome (data not shown).
Impact of administered treatment on outcome
We analyzed the treatment outcome also according to the
administered treatment, since an important proportion of patients
did not receive the allocated treatment according to the
randomization (Figure 1). More patients in the APBSCT arm
received the allocated treatment compared with the ABMT arm:
104 and 93 patients, respectively. Twenty-two patients in the
ABMT arm received an APBSCT rescue after a median of 35 days
(range: 0–195 days) after the BM stem cell infusion. The OS was
not signiﬁcantly different (P= 0.64) when comparing the 71
patients who received BM alone vs the 22 patients who received
APSC also as rescue with an HR of 1.2 (95% CI = 0.56–2.55).
The 5-year DFS of patients who received treatment according to
randomization was 40% in the APBSCT arm compared with 55% in
the ABMT arm with an HR of 1.68, 95% CI = 1.13–2.5 (P= 0.009).
The HR decreased to 1.4, 95% CI = 0.94–2.14 (P= 0.09) after
adjusting the treatment comparison by factors which appeared to
be of independent prognostic importance, including harvest
after mobilization and the drugs of the ﬁrst randomization
(Table 2). The corresponding 5-year survival was 50% and 65%,
respectively (Figure 4a) with an HR of APBSCT vs ABMT of 1.50,
95% CI = 0.97–2.3 (P= 0.065). After adjusting the treatment
outcome for all relevant factors, the HR remained stable with
1.53, 95% CI = 0.94–2.49 (P= 0.086).
In patients randomized for APBSCT (43 patients) and ABMT 53
(patients) and who did not receive their assigned stem cell source,
the distribution of usual prognostic factors was quite similar
(Table 1). However, patients in the APBSCT arm had received
signiﬁcantly less frequently DNR: 21% vs 40% in the patients
group who received APBSCT according to randomization (Table 2).
In addition, the percentage of patients with failed mobilization
was signiﬁcantly higher, 77% vs 4% in the group who did not
receive APBSCT according to randomization compared with the
group who did receive APBSCT as planned.
The 5-year DFS of the patients who did not receive treatment
according to the randomization was 42% in the APBSCT arm
compared with 30% in the ABMT arm with an estimated HR of
0.65, 95% CI = 0.88–1.11 (P= 0.11). After adjusting the treatment
Table 2. The distribution of ﬁrst randomization (type of anthracycline) and the harvests, deﬁned by highest count of CD34+ cells × 106/kg, by
randomized treatment group (APBSCT vs ABMT) and by treatment actually given in the two randomized groups
Treatment group Treatment given Treatment not given
APBSCT ABMT APBSCT ABMT APBSCT ABMT
Total, n (%) 146 146 104 93 42 53
First randomization
DNR 51(35) 46 (31) 9 (21) 18 (34) 42 (40) 28 (30)
MTZ 51 (35) 52 (36) 19 (45) 16 (30) 32 (31) 36 (39)
IDA 44 (30) 48 (33) 14 (33) 19 ( 36) 30 (29) 29 (31)
N with harvests (%) 118 116 87 76 31 40
Harvestsa
No harvest 28 (23.7) 24 (20.7) 4 (15) 13 (17) 24 (77) 11 (28)
Ho1 15 (12.7) 18 (15.5) 11 (13) 15 (20) 4 (13) 3 (8)
1⩽Ho7 42 (35.6) 46 (39.7) 39 (45) 33 (43) 3 (10) 13 (33)
H⩾ 7 33 (28.0) 28 (24.1) 33 (38) 15 (20) 0 13 (33)
5-year DFS (%) 41 46 44 57 42 30
HR: APBSCT vs ABMTb 1.17 (0.85–1.59) 1.68 (1.07–2.62) 0.65 (0.88–1.11)
5-year survival (%) 50 55 53 68 50 40
HR: APBSCT vs ABMTb 1.11 (0.79–1.56) 1.53 (0.94–2.49) 0.68 (0.39–1.10)
Abbreviations: ABMT= autologous BMT; APBSCT= autologous peripheral blood SCT; DFS=disease-free survival; HR= hazard ratio; IDA= idarubicin;
MTZ=mitoxantrone. aHighest (H) count of CD34+ cells × 106/kg body weight during a single apheresis. bHazard ratio adjusted for all relevant prognostic
factors, including the drugs of the ﬁrst randomization and the number of CD34+ cells in the harvests (95% conﬁdence intervals).
Table 3. Stem cell harvests in each treatment group
Treatment group
APBSCT ABMT
No. (%) No. (%)
Total 118 (100) 116 (100)
Number of BM harvests in ﬁrst CR
1 9 (7.6) 84 (72.4)
2 — 6 (5.2)
No BM harvest 109 (92.4) 26 (22.4)
Number of rounds of PBSC aphereses
0 12 (10.2) 17 (14.7)
1 80 (67.8 ) 94 (81.0)
2 14 (11.9) 5 (4.3)
3 12 (10.2) —
Abbreviations: ABMT= autologous BMT; APBSCT= autologous peripheral
blood SCT.
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Table 4. Results of the multivariate Cox model regarding disease-free survival (DFS) and disease-free interval (DFI)
Parameter Endpoint
DFS DFI
HR (95% CI) P-value HR (95% CI) P-value
Model 1
Randomized group: APBSCT vs ABMT 1.07 (0.76–1.52) 0.69 1.08 (0.75–1.54) 0.68
Model 2
Randomized group: APBSCT vs ABMT 0.94 (0.66–1.33) 0.72 0.92 (0.64–1.33) 0.66
CD34+ cell harvest: no harvest vs Ho1 1.82 (0.86–3.83) 0.12 2.06 (0.95–4.48) 0.07
CD34+ cell harvest: 1⩽Ho7 vs Ho1 1.86 (0.94–3.69) 0.08 1.98 (0.96–4.06) 0.06
CD34+ cell harvest: H⩾ 7 vs Ho1 3.62 (1.8–7.29) 0.0003 4.34 (2.09–9.01) o0.0001
Cytogenetics group: inconclusivea vs good 3.5 (1.77–6.92) 0.0003 2.969 (1.485–5.936) 0.0021
Cytogenetics group: intermediate vs good 3.01 (1.53–5.92) 0.001 2.963 (1.503–5.842) 0.0017
Cytogenetics group: other/poor vs good 4.29 (2.14–8.59) o0.0001 4.059 (2.01–8.195) o0.0001
Age (years): 26–45 vs o26 0.66 (0.37–1.17) 0.16 0.63 (0.35–1.12) 0.12
Age (years): 46–60 vs o26 0.89 (0.51–1.54) 0.68 0.75 (0.43–1.31) 0.32
Numbers of cycles to reach CR: 2 vs 1 2.46 (1.34–4.5) 0.004 2.41 (1.31–4.44) 0.005
First randomization: MTZ vs DNR 0.95 (0.6–1.5) 0.82 0.89 (0.55–1.43) 0.62
First randomization: IDA vs DNR 1.27 (0.83–1.96) 0.27 1.25 (0.81–1.95) 0.32
Abbreviations: ABMT= autologous BMT; APBSCT= autologous peripheral blood SCT; CI= conﬁdence interval; HR= hazard ratio; IDA= idarubicin;
MTZ=mitoxantrone. aPatients with unknown cytogenetic data were classiﬁed as 'inclusive' in a separate cytogenetic risk group. For preparatory models of
Model 2, see models 1/3 in Supplementary Table 1. H: highest count of CD34+ cells × 106/kg body weight during a single apheresis. A total of 234 patients
were included in these models restricted to patients with information on mobilized stem cell harvests (118 patients in the APBSCT arm and 116 patients in the
ABMT arm).
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Figure 3. Subgroup analyses regarding disease-free survival comparing the APBSCT and ABMT arms according to cytogenetic and CD34+ cell
yield using forest plot technique.
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comparison by factors which appeared to be of independent
prognostic importance, including harvest after mobilization and
the drugs of the ﬁrst randomization (Table 2), the HR was 0.52,
95% CI = 0.29–0.94 (P= 0.028). The corresponding 5-year survival
was 50% and 40%, respectively (Figure 4b), with a hazard ratio of
APBSCT vs ABMT of 0.68, 95% CI = 0.39–1.20 (P= 0.18). After
adjusting the treatment outcome for all relevant factors, the HR
decreased further to 0.58, 95% CI = 0.31–1.10 (P= 0.09).
DISCUSSION
APBSCT is an appealing alternative to ABMT in view of the faster
hematopoietic recovery after APBSCT, but an increased relapse
risk after APBSCT has remained a serious concern. Therefore, we
amended the AML-10 trial to address this issue.4 The two
investigational drugs in this study had a signiﬁcant (Po0.001)
impact on the application of ASCT. ASCT was performed in 54% of
cases who received the ﬁrst consolidation course in the DNR arm
vs 41% and 47% in mitoxantrone and idarubicin, respectively. This
difference was due to a lower success rate of stem cell collection
in the mitoxantrone and idarubicin arms,4,17 comparable to the
49% success rate in a recent study.18 Studies with higher success
rates have randomized patients at a later time point after recovery
of the last consolidation course excluding patients with prolonged
hypoplasias and early relapses.3 The randomization of the present
study occurred 28 days after the start of the consolidation course,
leading to a successful ASCT rate of 69% and 61% in the APBSCT
and ABMT arm, respectively.
Our trial shows no signiﬁcant differences in terms of DFS (main
endpoint), OS and incidence of relapse between the APBSCT and
ABMT arms, when analyzed on an intention-to-treat analysis. This
lack of signiﬁcant difference might be due to a true low treatment
difference, to a low statistical power (for example, 50% for
detecting an 11% increase in 5-year DFS rate), as only 162 DFS
were reported in this study (see sample size calculations in
Supplementary Data), and/or a relatively low rate of SCT
performed according to randomization. However, duration of
aplasia, transfusion need, days on i.v. antibiotics or duration of
hospitalization were signiﬁcantly favorable in APBSCT arm. The
mortality incidence in ﬁrst CR was low in both arms: 4% and 5%
after APBSCT and ABMT, respectively. Other retrospective
studies13,14 showed higher relapse rates after APBSCT after
reinfusion of higher numbers of leukemic CD34+ cells.14 In a
previous analysis,17 we showed that high numbers of mobilized
CD34+ cells were an important, independent poor prognostic
factor. Our present study conﬁrms the shorter DFS in the group
with high numbers of mobilized CD34+ cells when compared with
low numbers of mobilized CD34+ cells or a failed mobilization.
The prognostic impact of the number of mobilized stem cells
appeared independent from the cytogenetic risk groups which
were the most powerful prognostic factor. The DFS in the APBSCT
and ABMT arms was not different in the four groups deﬁned by
the number of mobilized CD34+ cells, conﬁrming that the number
of mobilized CD34+ cells is a poor prognostic factor indepen-
dently from the treatment given after mobilization. These data
conﬁrm that high numbers of mobilized CD34+ cells have a
negative impact of outcome even without infusing the mobilized
stem cells, conﬁrming the observations using ﬂow cytometry to
study leukemic stem cell contamination in the harvests by
leukemia-associated phenotypes.19
Twenty-two patients, randomized to ABMT received APBSCT as
rescue. The OS of these 22 patients was not different when
compared with the 71 patients who received BM alone (P= 0.64).
Moreover, we analyzed the outcome in patients who received
treatment according to randomization vs patients who did not
receive this treatment (Table 2 and Figure 3). The 5-year survival in
the APBSCT arm did not change irrespective of whether patients
received APSCT according to randomization or not. However, the
5-year survival of patients in the ABMT arm was 65% when
patients were treated according to randomization vs 40% in
patients who did not receive ABMT. This difference can be
explained by the shorter interval between randomization and
ASCT in the APBSCT arm leading to less relapses before ASCT in
this arm (two relapses) compared with the ABMT arm (12 relapses)
and by relatively high number of patients (33%) in this group
(randomized to ABMT, but no ABMT administered) with 47 × 106
mobilized CD34+ cells/kg (Table 2).
The results of this study conﬁrm the results of earlier
retrospective studies showing that higher CD34+ cell counts in
the mobilized stem cell harvests correlate with a high frequency of
cells with an abnormal phenotype, a higher level of minimal
residual disease, and a higher relapse risk.19,20 In an earlier
analysis, we showed that the duration of hypoplasia after the
consolidation course was short in the group of patients with a
high CD34+ cell harvest, probably reﬂecting an in vitro purging of
the normal and leukemic stem cells.17 A shorter duration of
pancytopenia after the consolidation course, and especially the
duration of neutropenia, was associated with a worse prognosis.
Genetic polymorphisms in the ABCG2 transmembrane transporter
protein may contribute to differential survival outcomes in AML
patients by a decreased drug efﬂux and higher cytotoxicity in both
normal progenitors and AML cells and a longer hypoplasia after
the consolidation course.16
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Figure 4. Duration of OS from randomization in patients randomized to receiving mobilized autologous PBSC (red curve) or autologous BM
stem cells (blue curve): (a) patients who received treatment according to randomization; (b) patients who received other treatment or no
treatment (see ﬂow diagram in Figure 1). N=number of patients; O=observed number of events (death); P-value given by the log-rank test.
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Targeted therapy might be relevant for speciﬁc patient groups.
However, addition of gemtuzumab ozogamicin to the remission-
induction course conferred a signiﬁcant survival beneﬁt for
patients with favorable cytogenetics, but no beneﬁt for patients
with poor-risk disease.21 Similarly, addition of gemtuzumab
ozogamicin to the consolidation course did not improve outcome
after APBSCT.18
In conclusion, randomization between APBSCT and ABMT did
not result in signiﬁcantly different outcomes in terms DFS, OS and
relapse incidence, but hematopoietic recovery after APBSCT was
substantially faster. This resulted in lower requirement of
transfusions and antibiotics and in a 2-week shorter hospitaliza-
tion. High numbers of CD34+ cells obtained during the ﬁrst round
of mobilization was a strong adverse prognostic factor, indepen-
dent of cytogenetic features and independent of the administered
treatment. Patients with high numbers of ‘mobilizable’ CD34+
cells after the ﬁrst consolidation course have a poor prognosis.
These patients may beneﬁt from allo-SCT or new alternative
treatment approaches, similar to patients with adverse risk
cytogenetic or molecular features.22
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